Identification of Quinolinols as Activators of TEAD-Dependent Transcription
作者:Ajaybabu V. Pobbati、Tom Mejuch、Sayan Chakraborty、Hacer Karatas、Sakshibeedu R. Bharath、Stéphanie M. Guéret、Pierre-Alexis Goy、Gernot Hahne、Axel Pahl、Sonja Sievers、Ernesto Guccione、Haiwei Song、Herbert Waldmann、Wanjin Hong
DOI:10.1021/acschembio.9b00786
日期:2019.12.20
has been physiologically shown to bind palmitate. Herein, a TEAD-palmitate interaction screen was developed to select small molecules occupying the palmitate-binding pocket (PBP) of TEADs. We show that quinolinols were TEAD-binding compounds that augment YAP/TAZ-TEAD activity, which was verified using TEAD reporter assay, RT-qPCR, and RNA-Seq analyses. Structure-activity relationship investigations uncovered
A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A
作者:William A. Harrell、Rebecca C. Vieira、Susan M. Ensel、Vicki Montgomery、Rebecca Guernieri、Vanessa S. Eccard、Yvette Campbell、Virginia Roxas-Duncan、John H. Cardellina、Robert P. Webb、Leonard A. Smith
DOI:10.1016/j.bmcl.2016.11.019
日期:2017.2
considerable flexibility in the binding site. We designed a limited study to investigate this flexibility and probe structure-activity relationships; utilizing the Betti reaction, a 36 compound matrix of quinolinol BoNT/A LC inhibitors was developed using three 8-hydroxyquinolines, three heteroaromatic amines, and four substituted benzaldehydes. This study has revealed some of the most effective quinolinol-based
我们最初发现的BoNT / A的8-羟基喹啉抑制剂和其中一种活性较高的对映体的对映异构体的分离/测试表明,其结合位点具有相当大的灵活性。我们设计了一项有限的研究来调查这种灵活性并探讨结构与活性之间的关系。利用Betti反应,使用三种8-羟基喹啉,三种杂芳族胺和四种取代的苯甲醛开发了一种36种喹啉基BoNT / A LC抑制剂的化合物基质。这项研究揭示了迄今为止一些最有效的基于喹啉醇的BoNT / A抑制剂,在离体测定中,有7种化合物的IC 50值⩽1μM和11种在⩽2μM时有效。
Prolylhydroxylase/ATF4 inhibitors and methods of use for treating neural cell injury or death and conditions resulting therefrom
申请人:CORNELL UNIVERSITY
公开号:US10716783B2
公开(公告)日:2020-07-21
Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R1 is a cyclic group containing at least three and up to seven carbon atoms and optionally containing one or more heteroatoms selected from O, N, and S, and optionally attached to the shown carbon atom by a linking group; R2 is independently selected from said cyclic groups of R1 and acyclic hydrocarbon groups R5 containing up to twenty carbon atoms; R3 is selected from hydrogen atom and hydrocarbon groups containing up to six carbon atoms; R6 and R7 are independently selected from hydrogen atom, hydrocarbon groups containing up to three carbon atoms, halogen atom, and polar groups, as well as methylene-linked versions thereof; and t is 0 or 1.
PROLYLHYDROXYLASE/ATF4 INHIBITORS FOR TREATING NEURAL CELL INJURY
申请人:Cornell University
公开号:EP3079697B1
公开(公告)日:2021-02-03
GLYCOSAMINOGLYCAN INHIBITORS
申请人:Crawford Brett E.
公开号:US20120295890A1
公开(公告)日:2012-11-22
Provided herein are chondroitin sulfate inhibitors, including modulators of glycosylation, and/or sulfation of galactose or N-acetyl galactosamine glycosaminoglycans.